Clinical meaning
the clinician managing hemodialysis patients applies advanced understanding of renal replacement therapy modalities, vascular access, and dialysis prescription. Hemodialysis removes uremic toxins and excess fluid through diffusion (solute movement down concentration gradient across a semipermeable membrane -- small molecules like urea and creatinine cross readily, larger molecules like beta-2 microglobulin require high-flux membranes) and ultrafiltration (convective fluid removal driven by transmembrane pressure gradient). Dialysis adequacy is measured by Kt/V (target greater than or equal to 1.2 for thrice-weekly HD, where K = dialyzer clearance, t = time, V = volume of distribution of urea) and urea reduction ratio (target greater than or equal to 65%). Vascular access hierarchy: arteriovenous fistula preferred (lowest infection and thrombosis rates, best long-term patency, requires 6-8 weeks maturation), arteriovenous graft if native fistula not feasible (higher thrombosis and infection rates, usable within 2-4 weeks), tunneled central venous catheter as last resort (highest infection rate, central venous stenosis risk). The clinician manages intradialytic complications (hypotension -- most common, managed by ultrafiltration rate reduction, saline bolus, and reassessment of dry weight; muscle cramps, nausea, headache, chest pain), adjusts dialysis prescription parameters, manages CKD-mineral bone disease, erythropoiesis-stimulating agent therapy, and access-related complications.